Salbutamol inhalation - Adamis Pharmaceuticals

Drug Profile

Salbutamol inhalation - Adamis Pharmaceuticals

Alternative Names: Albuterol HFA - Adamis Pharmaceuticals; Albuterol HFA aerosol - Adamis Pharmaceuticals; APC 2000; APC 2000 HFA; Salbutamol HFA - Adamis Pharmaceuticals; Salbutamol HFA aerosol - Adamis Pharmaceuticals

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Bronchospasm

Most Recent Events

  • 08 Feb 2017 Phase-II clinical trials in Bronchospasm in USA (Inhalation) (Adamis Pharmaceuticals pipeline, February 2017)
  • 16 Apr 2015 Adamis plans a phase III trial for Asthma
  • 01 Jan 2014 Phase-II clinical trials in Asthma (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top